Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
JPI Healthcare Co., Ltd. is a leading provider in the advanced medical equipment and technology sector, specializing in comprehensive digital X-ray imaging solutions. The company develops and manufactures a broad portfolio of diagnostic imaging products, including proprietary X-ray grids, digital upgrades, computed radiography equipment, anesthesia machines, patient monitors, ultrasounds, X-ray protective apparel, and automated disinfectors. JPI Healthcare serves both human and veterinary healthcare markets, leveraging innovative, high value-added technologies such as their StriXion and Detect imaging devices to enhance diagnostic accuracy and efficiency. Founded in Seoul, South Korea in 1980, the company plays a critical role in supporting global healthcare professionals by delivering reliable, high-quality imaging systems and components. JPI Healthcare has established itself as Korea’s premier expert in imaging solutions, focusing on expanding its reach through strategic partnerships and ongoing product development to meet the evolving demands of the medical imaging industry.
€7,170.00
€190.00 (-2.58%)
Live · 05:25 PM
10.03% operating margin is respectable but not wide. ROIC at 6.31%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 7.6%, steady but not accelerating.
At 10965x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
10964.9x earnings, 29768.7x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩47.97B
▲ +7.6% YoY
Net Income (TTM)
₩5.03B
▼ -12.8% YoY
Op. Margin
8.05%
▲ +1.3pp YoY
ROIC
6.31%
▲ +0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩2.17B
▲ +127.7% YoY
Op. Cash Flow (TTM)
₩7.17B
▲ +45.5% YoY
Net Debt
-₩20.60B
Net Cash Position
Cash & Equiv.
₩32.43B
Continue Research
At a P/E of 10,964.9 and a price-to-free-cash-flow of 29,768.7, JPI Healthcare Co. (0010V0.XKRX) trades below a two-stage DCF intrinsic value of about KRW 13,492.76 per share, so at KRW 7,170.00 the stock looks undervalued (88.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, JPI Healthcare Co. scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 13,492.76 per share for 0010V0.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 10,119.57. At today's KRW 7,170.00, that puts the stock about 88.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
JPI Healthcare Co. scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 8.1% operating margin and a 6.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 0010V0.XKRX currently trades below its estimated intrinsic value and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.